Cell Therapeutics, Inc. today announced that it has submitted a supplemental Biologics License Application with the U.S. FDA for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma.
The details can be read here.
No comments:
Post a Comment